Investigation Overview
After Eli Lilly & Co. lost more than 10% in stock value an investigation on behalf of investors in Eli Lilly & Co. (Public, NYSE:LLY) shares concerning potential violations of Federal Securities laws in connection with the New Drug Application for Eli Lillys diabetes drug BYDUREON was announced. The investigation by a law firm on behalf of investors in LLY shares concerns whe...
You must register (for free) or login to view the entire investigation.